With EGFR mutation status available in 33 (46.5%) patients, to the best of our knowledge, we analyzed the second largest cohort of EGFR‐mutated early‐stage NSCLC patients receiving SABR currently available in the literature. Here, EGFR is linked to non-small cell lung carcinoma.